Publication | Open Access

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer

Non-small-cell Lung CancerTumor Mutation BurdenMedicineCheckpoint Inhibitor TreatmentImmunologyPathologyCancer GenomicsBronchial NeoplasmImmune Checkpoint InhibitorOncologyLung Cancer